Despite increased openness by regulators and technological progress, the adoption of alternatives to animal testing remains challenging. The need for data validation by agencies and companies is a big factor.
Although alternatives are increasingly becoming available, apprehension and regulatory demands remain key obstacles to the use of non-animal-based models in preclinical pharmaceutical testing.
Some researchers remain apprehensive of regulatory demands around alternative models despite recent changes in legislation in key markets.
According to a recent survey carried out by the non-profit Pistoia Alliance during two webinars, which featured over 350 representatives...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
